Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 4, 2026
Reporting Period: Announcement of the 2025 Annual Report
Novo Nordisk is a leading global healthcare company headquartered in Denmark, founded in 1923. The company focuses on defeating serious chronic diseases, with a heritage in diabetes. It employs approximately 68,800 people across 80 countries and markets products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange (NVO).
Key Financial Metrics
The provided filing text serves as a cover announcement for the 2025 Annual Report and does not contain specific financial data points. The following metrics are not present in this document:
- Revenue: Not provided in this filing.
- Profit: Not provided in this filing.
- Cash Flow: Not provided in this filing.
- Margins: Not provided in this filing.
- Debt and Liquidity: Not provided in this filing.
Investors are directed to the attached iXBRL annual report for detailed financial statements.
Material Changes
The filing text does not provide specific comparative financial data or material changes versus the prior period. It solely confirms the publication of the 2025 annual report.
Guidance, Outlook, and Risks
Management Commentary: The company states its purpose is to drive change to defeat serious chronic diseases through scientific breakthroughs, expanding access to medicines, and working to prevent and cure disease.
Guidance and Outlook: No specific financial guidance or forward-looking projections are included in this announcement text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Key Facts for Investor Verification
- Verify the full 2025 Annual Report (attached in iXBRL format) for actual revenue, profit, and cash flow figures.
- Confirm the company's operational scale: ~68,800 employees in 80 countries with a market presence in ~170 countries.
- Note the listing details: B shares on Nasdaq Copenhagen and ADRs (NVO) on the NYSE.
- Review the attached document "NOVO-2025-12-31-1-en" for the complete financial performance of the 2025 fiscal year.